Leukemia research

Leukemia research

010 CD72 NANOBODY CAR-T CELLS HAVE POTENT ANTITUMOR EFFICACY IN B CELL MALIGNANCIES.

Leukemia research

W. Temple, M. Nix, G. Wicaksono, D. Wang, P. Phojanakong, V. Steri, B. Hann, M. Hermiston, A. Wiita

049 A TARGETED GENE EXPRESSION CLASSIFIER IDENTIFIES PEDIATRIC T-ALL PATIENTS AT HIGH RISK FOR END INDUCTION MINIMAL RESIDUAL DISEASE POSITIVITY.

Leukemia research

L. Meyer, Ritu P. Roy, B. Huang, S. Kimura, Petri Polonen, C. Delgado-Martin, T. Vincent, T. Ryan, B. Wood, Y. Liu, J. Zhang, C. Mullighan, T. Horton, M. Loh, M. Devidas, E. Raetz, R. Hayashi, S. Winter, K. Dunsmore, S. Hunger, D. Teachey, M. Hermiston, Adam B. Olshen

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.

Leukemia research

Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP

Search form

You are here

010 CD72 NANOBODY CAR-T CELLS HAVE POTENT ANTITUMOR EFFICACY IN B CELL MALIGNANCIES.

049 A TARGETED GENE EXPRESSION CLASSIFIER IDENTIFIES PEDIATRIC T-ALL PATIENTS AT HIGH RISK FOR END INDUCTION MINIMAL RESIDUAL DISEASE POSITIVITY.

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.